ASP4396 / Astellas - LARVOL DELTA

Non-clinical study of ASP4396, a novel KRAS G12D degrader, shows remarkable anti-tumor activity in KRAS G12D mutant cancer models (AACR-NCI-EORTC 2025) - P1 | "A series of our non-clinical studies suggested that ASP4396 could be a promising therapeutic agent for patients with tumors harboring the KRAS G12D mutation. With these results, a Phase I clinical trial is underway (NCT06364696). We are conducting further characterization to understand the differences in the profiles of ASP3082 and ASP4396 due to the differences in E3 ligase and their impact on their respective efficacy and safety profiles."

Clinical • Preclinical • Oncology • Pancreatic Cancer • Solid Tumor • KRAS

Trial in progress: Phase 1 study of the selective protein degrader ASP4396 in patients with locally advanced or metastatic solid tumors with KRAS G12D mutations. (ASCO 2025) - P1 | "Data will be summarized descriptively (mean, standard deviation, median) for continuous endpoints, and by counts and percentages for categorical endpoints. Study enrollment is ongoing."

Clinical • Metastases • P1 data • Oncology • Solid Tumor • Targeted Protein Degradation • KRAS

A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors (clinicaltrials.gov) - P1 | N=175 | Recruiting | Sponsor: Astellas Pharma Inc | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor • KRAS

A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors (clinicaltrials.gov) - P1 | N=175 | Not yet recruiting | Sponsor: Astellas Pharma Inc

Metastases • New P1 trial • Oncology • Solid Tumor • KRAS